|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:brand
|
gptkb:Zyprexa_Relprevv
gptkb:Zyprexa_Zydis
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
NC T00000123
NC T00000124
NC T00000125
NC T00000126
NC T00000127
|
|
gptkbp:code
|
N05 A H03
|
|
gptkbp:contraindication
|
hypersensitivity to olanzapine
|
|
gptkbp:dosage_form
|
injection
oral tablet
sublingual tablet
|
|
gptkbp:effective_date
|
1996-09-30
|
|
gptkbp:formulation
|
gptkb:tablet
injectable
orally disintegrating tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zyprexa
|
|
gptkbp:ingredients
|
gptkb:olanzapine
C17 H20 N4 O2 S
|
|
gptkbp:interacts_with
|
antidepressants
CNS depressants
antihypertensives
|
|
gptkbp:is_used_for
|
schizophrenia
bipolar disorder
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
30 hours
|
|
gptkbp:manager
|
oral
intramuscular
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
gptkb:Person
adults
adolescents
|
|
gptkbp:side_effect
|
metabolic syndrome
drowsiness
constipation
dry mouth
weight gain
increased appetite
hyperlipidemia
hyperglycemia
extrapyramidal symptoms
neuroleptic malignant syndrome
|
|
gptkbp:type_of
|
132539-06-1
|